US5238924A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of renal diseases with ace inhibitors
Assignee: The Brigham and Women's Hospital Inc
•
Filing: 1991-11-13
•
Granted: 1993-08-24
•
Expires: 2011-11-13
Abstract
Abstract There is disclosed the use of angiotensin converting enzyme (ACE) inhibitors to alter the progression of renal diseases by affecting intraglomerular hemodynamics and proteinuria; i.e., affecting blood pressure within the functioning, filtering tissue of the kidney and the quantity of albumin in the urine.
Inventors
- 👤 Ronald D. Smith
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 21:11
CPC Classifications
C; C07; C07K; C07K5/00; C07K5/04; C07K5/06; C07K5/06086; A; A61; A61K; A61K38/00; A61K38/16; A61K38/55; A61K38/556; C07K5/06139
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
57 words
A method of treating progressive renal failure which is manifested by such deficiences as intraglomerular hypertension, progressive glomerular sclerosis, progressive proteinuria, azotemia, regardless of the etiology of the initial renal insult which method comprises administering to a patient in need of such treatment a renal failure inhibiting amount of an angiotensin converting enzyme inhibitor carboxyalkyl dipeptide compound.
Claim 2
Independent Claim
57 words
A method of treating progressive renal failure which is manifested by such deficiences as intraglomerular hypertension, progressive glomerular sclerosis, progressive proteinuria, azotemia, regardless of the etiology of the initial renal insult which method comprises administering to a patient in need of such treatment a renal failure inhibiting amount of an angiotensin converting enzyme inhibitor carboxyalkyl dipeptide compound.
Claim 3
Dependent Claim
34 words
The method of claim 1 wherein said angiotensin converting enzyme inhibitor compound is a member selected from the group consisting of carboxyalkyl dipeptide derivatives; 1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline; 2-[N-(S)-1-ethoxy-carbonyl-3-phenylpropyl)-S-alanyl]-cis,endo-2-aza-bicyclo[3,3,0]octane-3(S)-carboxylic acid; N-((S)-1-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-N-(2-indanyl)-glycine; 1-(N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-cis,syn-octahydro-(H-indole-2-S)-carboxylic acid; 2-(N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl)-1,2,3,4-tetrahydroiso-isoquinoline-3(S)-carboxylic acid; and, 1-carboxymethyl-3(S)-(1(S)-ethoxycarbonyl-3-phenylpropylamino)-2,3,4,5-tetrahydro-1H[1]-benzazepine-2-one.
Claim 4
Dependent Claim
21 words
The method of claim 2 wherein said carboxyalkyl dipeptide derivatives are selected from the group consisting of: N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline; N-[1(S)-carboxy-3-phenylpropyl]-L-alanyl-L-proline; or, N-α-[1(S)-carboxy-3-phenylpropyl]-L-lysyl-L-proline.
Claim 5
Independent Claim
69 words
A method of treating progressive renal failure which is manifested by such deficiencies as intraglomerular hypertension, progressive glomerular sclerosis, progressive proteinuria, azotemia, regardless of the etiology of the initial renal insult which method comprises administering to a person in need of such treatment a renal failure inhibiting amount of an angiotensin converting enzyme inhibitor compound which is a member selected from the group consisting of: N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline; N-[1(S)-carboxy-3-phenylpropyl]-L-alanyl-L-proline; or, Nα-[1(S)-carboxy-3-phenylpropyl]-L-lysyl-L-proline.
Claim 6
Independent Claim
69 words
A method of treating progressive renal failure which is manifested by such deficiencies as intraglomerular hypertension, progressive glomerular sclerosis, progressive proteinuria, azotemia, regardless of the etiology of the initial renal insult which method comprises administering to a person in need of such treatment a renal failure inhibiting amount of an angiotensin converting enzyme inhibitor compound which is a member selected from the group consisting of: N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline; N-[1(S)-carboxy-3-phenylpropyl]-L-alanyl-L-proline; or, Nα-[1(S)-carboxy-3-phenylpropyl]-L-lysyl-L-proline.
Claim 7
Independent Claim
30 words
A method of treating progressive renal failure that comprises administering to a patient in need of such treatment a renal failure inhibiting amount of an angiotensin converting enzyme inhibitor compound.
Claim 8
Independent Claim
30 words
A method of treating progressive renal failure that comprises administering to a patient in need of such treatment a renal failure inhibiting amount of an angiotensin converting enzyme inhibitor compound.
Claim 9
Dependent Claim
37 words
The method of claim 5 wherein said angiotensin converting enzyme inhibitor compound is a member selected from the group consisting of carboxyalkyl dipeptide derivatives; 1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline; 2-[N-(S)-1-ethoxy-carbonyl-3-phenylpropyl)-S-alanyl]-cis,endo-2-aza-bicyclo[3,3,0]octane-3(S)-carboxylic acid; N-((S)-1-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-N-(2-indanyl)-glycine; 1-(N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-cis,syn-octahydro-(H-indole-2-S)-carboxylic acid; 2-(N-[(S)-1-ethoxy- carbonyl-3-phenylpropyl]-L-alanyl)1,2,3,4-tetrahydroiso-isoquinoline-3(S)-carboxylic acid; and, 1-carboxymethyl-3(S)- (1(S)-ethoxycarbonyl-3-phenylpropylamino)-2,3,4,5-tetrahydro-1H [1]-benzazepine-2-one.
Claim 10
Dependent Claim
21 words
The method of claim 6 wherein said carboxyalkyl dipeptide derivatives are selected from the group consisting of: N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline; N-[1(S)-carboxy-3-phenylpropyl]-L-alanyl-L-proline; or, N-α-[1(S)-carboxy-3-phenylpropyl]-L-lysyl-L-proline.
Claim 11
Independent Claim
44 words
A method of treating progressive renal failure that comprises administering to a person in need of such treatment a renal failure inhibiting amount of an angiotensin converting enzyme inhibitor compound which is a member selected from the group consisting of: N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline; N-[1(S)-carboxy-3-phenylpropyl]-L-alanyl-L-proline; or, N-α-[1(S)-carboxy-3-phenylpropyl]-L-lysyl-L-proline.
Claim 12
Independent Claim
44 words
A method of treating progressive renal failure that comprises administering to a person in need of such treatment a renal failure inhibiting amount of an angiotensin converting enzyme inhibitor compound which is a member selected from the group consisting of: N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline; N-[1(S)-carboxy-3-phenylpropyl]-L-alanyl-L-proline; or, N-α-[1(S)-carboxy-3-phenylpropyl]-L-lysyl-L-proline.
Claim 13
Dependent Claim
14 words
The method of claim 1 wherein the progressive renal failure is caused by glomerulonephritis.
Claim 14
Dependent Claim
15 words
The method of claim 1 wherein the progressive renal failure is caused by diabetic nephropathy.
Claim 15
Dependent Claim
15 words
The method of claim 1 wherein the progressive renal failure is caused by normotensive diabetes.
Claim 16
Dependent Claim
14 words
The method of claim 4 wherein the progressive renal failure is caused by glomerulonephritis.
Claim 17
Dependent Claim
15 words
The method of claim 4 wherein the progressive renal failure is caused by diabetic nephropathy.
Claim 18
Dependent Claim
15 words
The method of claim 4 wherein the progressive renal failure is caused by normotensive diabetes.
Claim 19
Dependent Claim
14 words
The method of claim 5 wherein the progressive renal failure is caused by glomerulonephritis.
Claim 20
Dependent Claim
15 words
The method of claim 5 wherein the progressive renal failure is caused by diabetic nephropathy.
Claim 21
Dependent Claim
15 words
The method of claim 5 wherein the progressive renal failure is caused by normotensive diabetes.
Claim 22
Dependent Claim
14 words
The method of claim 8 wherein the progressive renal failure is caused by glomerulonephritis.
Claim 23
Dependent Claim
15 words
The method of claim 8 wherein the progressive renal failure is caused by diabetic nephropathy.
Claim 24
Dependent Claim
15 words
The method of claim 8 wherein the progressive renal failure is caused by normotensive diabetes.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-08-23 | 1997-02-22 | 1997-08-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-08-23 | 2001-02-22 | 2001-08-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-08-23 | 2005-02-22 | 2005-08-24 | $7700.00 | Window Closed / Lapsed |